Denmark medical device registration timeline
Source-linked clocksDanish Medicines Agency (DKMA) review clocks and end-to-end planning ranges, using the 4-class (I, IIa, IIb, III) — EU MDR classification system.
| Class / pathway | Review clock | Planning total | With prior approval | Provenance |
|---|---|---|---|---|
| Class I(Self-declaration (no notified body)) MDR Art. 52(7): non-sterile, non-measuring, non-reusable-surgical Class I devices are self-declared, so no authority or notified body reviews the file and there is no review clock | 0 days | 6-9 months | — | Verified |
Denmark Medical Device Registration Process
Step-by-step DKMA registration process. Total estimated timeline: 6-9 months.
Step 1: Pre-Submission Preparation
1-3 monthsGather technical documentation, quality management system (QMS) records, and clinical data required by DKMA. Appoint a EU Authorized Representative.
Step 2: Application Submission
1-2 weeksSubmit complete registration dossier to DKMA including device description, risk analysis, and testing reports.
Step 3: Administrative Review
2-4 weeksDKMA reviews application for completeness. May request additional documents or clarifications.
Step 4: Technical Evaluation
0 daysIn-depth technical assessment of device safety and performance. DKMA may issue questions.
Step 5: Registration Approval
1-2 weeksUpon successful review, DKMA issues Denmark market authorization certificate.
- EU Authorized Representative (for non-EU manufacturers)
- Clinical investigation decision for class I and non-invasive IIa/IIb no later than 45 days after validation (MDR Art. 70(5); § 17(3) BEK 1731/2025); substantial modifications processed in 38 days
- Ethics committees notify DKMA within 25 days of validation for supplementary-information requests, likewise DKMA (§§ 15-16 BEK 713/2022); expert-extension notice within 7 days for invasive IIa/IIb and III
- Distributor and specialty-retailer registration processed within 14 days of receipt (valid from the submission date)
Reviewed 2026-08-29. End-to-end totals remain planning estimates.